NeoThetis Liquid Biopsy

NeoThetis is intended for patients diagnosed with solid tumours who:

• Have tumours that are inaccessible or unsuitable for tissue biopsy
• Have limited or insufficient tumour tissue available for molecular analysis
• Are unfit or not clinically recommended to undergo invasive biopsy procedures
• Need rapid results to support timely treatment decisions
• Do not respond to current therapy and require re-evaluation for potential resistance mechanisms
• Require molecular profiling to guide targeted therapy or immunotherapy selection
• Require ongoing monitoring of tumour evolution during disease progression

NeoThetis may support clinicians by:

• Enabling informed therapy selection through identification of clinically actionable genetic alterations
• Assessing eligibility for immunotherapy via key biomarkers, including microsatellite instability (MSI) and blood tumour mutational burden (bTMB)
• Providing a non-invasive alternative to tissue biopsy, reducing patient burden and procedural risks
• Capturing tumour heterogeneity by detecting alterations from both primary and metastatic sites
• Identifying mechanisms of treatment resistance to guide therapy re-evaluation
• Supporting timely clinical decision-making through fast turnaround of results
• Expanding treatment options by linking findings to approved therapies and relevant clinical trials

MSI status and bTMB score

The MSI status and the bTMB score of a tumour are reported along with their current /-approved immunotherapies.

Genetic alternations results

Variants of strong, potential, and uncertain significance are reported, along with /-approved or -recommended targeted therapies.

• Approved in indication
• Included in guidelines
• Lack of response

Eligibility on available clinical trials

Ongoing clinical trials are reported, expanding the patient’s treatment options.

Comprehensive and insightful information on the results is provided.

Following receipt of NeoThetis results, clinicians should consider:

• Informing the patient about the findings and recommending genetic counselling
• Identifying the most appropriate treatment strategy tailored to the patient’s tumour profile
• Evaluating eligibility for targeted therapies, immunotherapies, and relevant clinical trials

NeoThetis testing can help:

• Provide a non-invasive and safe alternative to tissue biopsy through a simple blood draw
• Deliver comprehensive tumour profiling, including genomic alterations and immunotherapy biomarkers such as MSI and bTMB
• Generate clinically actionable reports with interpretation of findings, associated therapies, and relevant clinical trials
• Support personalised treatment strategies based on the molecular characteristics of the tumour
• Enable timely clinical decision-making through fast turnaround of results
• Be applied across multiple solid tumour types, supporting broad clinical use